Xidolac Meltab 10 mg - 10mg

Tablet

Pack Size : 10 Tablet x 1 Strip

Generics : Ketorolac Tromethamine

Manufacturer : Beximco Pharmaceuticals Ltd.

Best Price * TK 120.00

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Etolac 10 mg Tab

Tk 10.50

Tablet Etorac 10 mg Tab Incepta Pharmaceuticals Ltd.

Tk 10.00

Tablet Ket 10 mg Delta Pharma Ltd

Tk 5.00

Tablet Minolac 10 mg Tab ACI Limited

Tk 10.07

Tablet Oradol 10 mg Tab Aristopharma Limited

Tk 10.00

More Information About - Xidolac Meltab 10 mg - 10mg

Description

Generic Name

Ketorolac Tromethamine

Precaution

Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely. Lactation: Drug excreted in breast milk with multiple doses; use contraindicated

Indication

Moderate to severe pain

Contra Indication

Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.

Dose

N/A

Side Effect

>10% Headache (17%),Somnolence (3-14%),Dyspepsia (12-13%),GI pain (12-13%),Nausea (12-13%) 1-10% Diarrhea (3-9%),Dizziness (3-9%),Pruritus (3-9%),Edema (1-3%),Increased blood urea nitrogen (BUN) (3%),Constipation (<3%),Purpura (<3%),Increased serum creatinine (2%),Drowsiness (6%),Hypertension (4%) <1% Abnormal thinking,Anaphylaxis,Blurred vision,Bronchospasm,Cholestatic jaundice,Depression,Difficulty in concentration,Dysgeusia,Euphoria,Hemolytic-uremic syndrome,Hepatitis,Hyperkalemia,Hyponatremia,Hypotension,Increased liver function test values,Insomnia,Laryngeal/lingual edema,Liver failure,Melena,Nervousness,Oliguria,Pallor,Peptic ulcer,Rash,Rectal bleeding,Stomatitis,Urinary frequency,Urinary retention,Vasodilation Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.

Pregnancy Category

Name : C

Description

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Mode of Action

Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme.

Interaction

May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam. Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.

Pregnancy Category Note

Pregnancy category: C; D in third trimester (may cause premature closure of ductus arteriosus) Lactation: Drug excreted in breast milk with multiple doses; use contraindicated

Adult Dose

Oral Adult Moderately Severe Acute Pain Short-term (<5 days) management of moderately severe acute pain that requires analgesia at opioid level; not indicated for minor or chronic painful conditions IV: 30 mg as single dose or 30 mg q6hr; not to exceed 120 mg/day IM: 60 mg as single dose or 30 mg q6hr; not to exceed 120 mg/day PO: 20 mg once after IV or IM therapy, THEN 10 mg q4-6hr; not to exceed 40 mg/day Elderly IV: 15 mg as single dose or 15 mg q6hr; not to exceed 60 mg/day IM: 30 mg as single dose or 15 mg q6hr; not to exceed 60 mg/day PO: 10 mg once after IV or IM therapy, THEN 10 mg q4-6hr; not to exceed 40 mg/day Dosing Considerations Always begin with parenteral therapy; oral administration indicated only as continuation of IV/IM dosing, if necessary Duration of therapy should not exceed 5 days

Child Dose

<2 years Safety and efficacy not established 2-16 years Single dose: 0.5 mg/kg IV/IM once; not to exceed 15 mg Multiple dose: 0.5 mg/kg IV/IM q6hr; not to exceed 5 days

Renal Dose

Renal impairment Severe: Contraindicated Moderate (moderately elevated serum creatinine): Use 50% of recommended dosage; not to exceed 60 mg/day IM/IV

Administration

N/A

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.